Skip to main content

Fluticasone Furoate

Intranasal Use in Allergic Rhinitis

Drugs volume 67, pages 1905–1915 (2007)Cite this article

Abstract

  • ▲ Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >2 years.

  • ▲ Fluticasone furoate nasal spray employs a novel delivery device with a unique side-actuated design, a short nozzle and a new trigger mechanism designed for ease of use.

  • ▲ In well controlled clinical trials, intranasal fluticasone furoate 110µg once daily for 2 weeks in adults and adolescents with seasonal allergic rhinitis reduced nasal and ocular symptoms, and improved health-related quality of life to a significantly greater extent than placebo.

  • ▲ Similarly, treatment with intranasal fluticasone furoate 110µg once daily for 4–6 weeks in adults and adolescents with perennial allergic rhinitis was superior to placebo in reducing nasal symptoms and with respect to overall response to therapy.

  • ▲ In children aged 6–11 years, fluticasone furoate nasal spray was shown to be effective in reducing the nasal symptoms of seasonal and perennial allergic rhinitis following treatment for 2 and 4 weeks, respectively.

  • ▲ Fluticasone furoate nasal spray was well tolerated in adults, adolescents and children aged 2–11 years, with an overall incidence of adverse events similar to that with placebo.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55(2): 116–34

    Article  PubMed  Google Scholar 

  2. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5 Pt 2): 478–518

    Article  PubMed  CAS  Google Scholar 

  3. Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004 Dec; 20(12): 1937–52

    Article  PubMed  Google Scholar 

  4. Van Hoecke H, Van Cauwenberge P. Critical look at the clinical practice guidelines for allergic rhinitis. Respir Med 2007 Apr; 101(4): 706–14

    Article  PubMed  Google Scholar 

  5. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. Epub 2007 Jun 8

  6. Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006 Feb; 15(1): 58–70

    Article  PubMed  Google Scholar 

  7. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma: ARIA workshop report. World Health Organization. J Allergy Clin Immunol 2001 Nov; 108 (5 Suppl.): S147–S334 (Pocket Guide [online]. Available from URL: http://www.whiar.org [Accessed 2007 Jul 26])

    Article  PubMed  CAS  Google Scholar 

  8. Berger W, Godfrey JW, Grant AC, et al. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S231

    Article  Google Scholar 

  9. US FDA. Veramyst™ (fluticasone furoate) nasal spray: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ [Accessed 2007 May 11]

  10. Biggadike K, Bledsoe R, Hassell A, et al. Fluticasone furoate (FF): interactions with the glucocorticoid receptor [abstract no. P219]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A91–2. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Google Scholar 

  11. Salter M, Biggadike K, Clackers M, et al. GW685698X — enhanced affinity for the glucocorticoid receptor: cellular and in vivo pharmacology [abstract no. 781]. 25th Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; Vienna

  12. Salter M, Biggadike K, Clackers M, et al. Fluticasone furoate (FF): enhanced cellular and tissue protection with a new selective glucocorticoid agonist [abstract no. P212]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A89. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Article  Google Scholar 

  13. Stuebner P. Effects of the novel intranasal glucocorticosteroid Gw685698 (200 µg once-daily) on seasonal allergic rhinitis (SAR) symptoms induced in the Vienna challenge chamber model (VCC) [abstract no. 1232]. J Allergy Clin Immunol 2006 Feb; 117 (2 Suppl. 1): S319

    Article  Google Scholar 

  14. Tripathy I, Sterling R, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 meg in children with perennial allergic rhinitis [abstract no. 909]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S232

    Article  Google Scholar 

  15. Patel D, Ratner P, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis [abstract no. 1191]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S305

    Article  Google Scholar 

  16. Gradman J, Caldwell M, Wolthers O. Knemometric assessment of short-term lower-leg growth in children with allergic rhinitis (AR) treated with fluticasone furoate (FF) nasal spray [abstract no. 1187]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304

    Article  Google Scholar 

  17. Allen A, Down G, Newlands A, et al. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects [abstract no. P210]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A89. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Article  Google Scholar 

  18. Hughes S, Shardlow P, Rousell V, et al. Disposition and metabolism of a novel enhanced affinity glucocorticoid, [14C]-fluticasone furoate (FF) after oral and intravenous (IV) administration in healthy male subjects [abstract no. P216]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A90–1. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Google Scholar 

  19. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007 Mar–Apr; 28(2): 216–25

    Article  PubMed  CAS  Google Scholar 

  20. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007 Jun; 119(6): 1430–7

    Article  PubMed  CAS  Google Scholar 

  21. Hampel Jr FC, Jacobs R, Martin B, et al. Once-daily fluticasone furoate nasal spray (FF) provides 24-hour symptom relief in subjects with seasonal allergic rhinitis (SAR) caused by mountain cedar pollen [abstract no. 1190]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304–5. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; 2007 Feb 23–27; San Diego (CA)

    Article  Google Scholar 

  22. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007 Sep; 62(9): 1078–84

    Article  PubMed  CAS  Google Scholar 

  23. Meltzer EO, Tripathy I, Lee J, et al. Once-daily fluticasone furoate nasal spray (FF) provides 24-hour relief of the nasal symptoms of seasonal allergic rhinitis (SAR) in children ages 2–11 years [abstract no. 1193]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S305

    Article  Google Scholar 

  24. Nathan R, Berger W, Yang W, et al. Once daily fluticasone furoate nasal spray (FFNS), a novel enhanced affinity steroid, provides 24-hour relief for the nasal symptoms of perennial allergic rhinitis (PAR) [abstract no. 254]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S65

    Article  Google Scholar 

  25. Vasar M, Houle P-A, Douglass JA, et al. A novel enhancedaffinity corticosteroid, once daily fluticasone furoate nasal spray (FFNS), provides 24-hour relief for the nasal symptoms of perennial allergic rhinitis (PAR) [abstract no. 626 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; Göteborg

  26. Maspero JF, Rosenblut A, Finn Jr A, et al. Once-daily fluticasone furoate nasal spray (FF) is safe and effective in the long-term treatment of perennial allergic rhinitis (PAR) in children ages 2 to 11 years [abstract no. 1189]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma and Immunology; 2007 Feb 23–27; San Diego (CA)

    Article  Google Scholar 

  27. Stanford R, Philpot E, Faris M, et al. Fluticasone furoate nasal spray once-daily improves quality of life in subjects with seasonal allergic rhinitis (SAR) [abstract no. P214]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A90. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Google Scholar 

  28. Given J, Toler T, Ellsworth A, et al. Once-daily fluticasone furoate nasal spray (FFNS) 110mcg improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the ragweed season [abstract no. 1188]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304

    Article  Google Scholar 

  29. van Bavel J, Toler T, Ellsworth A, et al. Once-daily fluticasone furoate nasal spray (FFNS) improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the mountain cedar pollen season [abstract no. 903]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S230

    Google Scholar 

  30. Stanford R, Philpot E, Faris M, et al. Fluticasone furoate nasal spray once-daily improves nocturnal quality of life in subjects with seasonal allergic rhinitis (SAR) [abstract no. P208]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A88–9. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)

    Google Scholar 

  31. Ratner P, Andrews C, van Bavel J, et al. Once-daily fluticasone furoate nasal spray (FF) effectively treats ocular symptoms of seasonal allergic rhinitis (SAR) caused by mountain cedar pollen [abstract no. 908]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S231. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; 2007 Feb 23–27; San Diego (CA)

    Article  Google Scholar 

  32. Fokkens W, Jogi R, Sidorenko I, et al. Fluticasone furoate nasal spray (FFNS) 110 µg once-daily is effective in seasonal allergic rhinitis (SAR) caused by grass pollen [abstract no. 352 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; Göteborg

  33. Meltzer E, Lee J, Tripathy I, et al. Study to assess the efficacy and safety of two doses of fluticasone furoate nasal spray in children with seasonal allergic rhinitis [abstract no. 343 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; Göteborg

  34. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007 Sep; 62(9): 1071–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: R. Nathan, Asthma & Allergy Associates, Colorado Springs, Colorado, USA; J. Maspero, Fundacion CIDEA, Buenos Aires, Argentina. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes based on any comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Paul L. McCormack & Lesley J. Scott

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Paul L. McCormack & Lesley J. Scott

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McCormack, P.L., Scott, L.J. Fluticasone Furoate. Drugs 67, 1905–1915 (2007). https://doi.org/10.2165/00003495-200767130-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767130-00010

Keywords

  • Allergic Rhinitis
  • Budesonide
  • Fluticasone
  • Fluticasone Propionate
  • Grass Pollen